基网络作为瘤免疫治疗中STING激动剂的协同载体
Yingcai Meng1,2, Jiaxin Huang1, Jinsong Ding1
1Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, Hunan, China.
新型-纳米粒子 (TMA NMs) 有效地提供STING激动剂ADU-S100,通过激活cGAS-STING通路和重塑瘤微环境来增强癌症免疫疗法.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 免疫学 免疫学 免疫学
背景情况:
- 循环GMP-AMP合成酶 (cGAS) 刺激干扰素基因 (STING) 途径对于先天免疫和癌症免疫疗法至关重要.
- 刺痛激动剂的临床应用受到稳定性,分娩和瘤表达变化的限制.
研究的目的:
- 开发一种新型的纳米载体用于STING激动剂ADU-S100,以改善癌症免疫疗法.
- 为了研究纳米载体和STING激动剂的协同作用.
主要方法:
- 合成封装ADU-S100的-网络 (TMA NMs),使用牛血清白蛋白表面修饰.
- 评估pH/GSH反应药物释放和细胞内输送.
- 评估STING通路激活,瘤微环境调制和体内抗瘤疗效.
主要成果:
- 在TMA NMs中,ADU-S100和Mn2+的pH/GSH响应释放得到证实,增强了STING通路的激活.
- 系统管理导致瘤积累和免疫抑制瘤微环境的显著重塑.
- TMA NMs诱导免疫细胞死亡,促进免疫细胞透,并抑制瘤生长.
结论:
- -网络作为STING激动剂的有效纳米载体,克服了传递挑战.
- 这种方法通过激活cGAS-STING通路并重新编程瘤微环境,协同增强免疫疗法.
- TMA NMs代表了促进癌症免疫治疗的有希望的平台.
更多相关视频
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
相关概念视频
Tumor Immunotherapy
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
The Tumor Microenvironment
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
